XML 26 R19.htm IDEA: XBRL DOCUMENT
v3.8.0.1

13. Stock-based Compensation | 12 Months Ended
--- | ---
Sep. 30, 2017
Share-based Compensation [Abstract] |
Stock-based Compensation | From time to time, the Company grants stock options and restricted stock awards to directors, officers and employees. These awards are valued at the grant date by determining the fair value of the instruments, net of estimated forfeitures. The value of each award is amortized on a straight-line basis over the requisite service period. Stock Options The following table summarizes stock option activity for the years ended September 30, 2017 and 2016:
|  |  |  |  | Weighted |  |  | Weighted |  |  |  |
|  |  |  |  | Average |  |  | Average |  |  |  |
|  | Number of |  |  | Exercise |  |  | Remaining |  |  |  |
|  | Shares |  |  | Price |  |  | Contractual Life |  |  | Intrinsic Value |
Outstanding at September 30, 2016 |  |  | 175,000 |  |  | $ | 11.22 |  |  |  | 3.75 |  |  | $ | 346,500 |
Granted |  |  | 36,668 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercised |  |  | – |  |  |  |  |  |  |  |  |  |  |  |  |
Forfeited |  |  | – |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding at September 30, 2017 |  |  | 211,668 |  |  | $ | 13.19 |  |  |  | 3.47 |  |  | $ | 454,417 |
Exercisable at September 30, 2017 |  |  | 175,000 |  |  | $ | 11.22 |  |  |  | 2.75 |  |  | $ | 428,750 |
The Company recognized compensation expense of $203,690 and $256,145 during the years ended September 30, 2017 and 2016, respectively, related to stock option awards granted to certain employees and officers based on the grant date fair value of the awards, net of estimated forfeitures. At September 30, 2017 the Company had $361,627 of unrecognized compensation expense (net of estimated forfeitures) associated with stock option awards which the Company expects will be recognized through December of 2021. The exercise price for stock options outstanding and exercisable at September 30, 2017 is as follows:
Outstanding |  |  | Exercisable |
Number of |  |  | Exercise |  |  | Number of |  |  | Exercise |
Options |  |  | Price |  |  | Options |  |  | Price |
| 31,250 |  |  | $ | 5.00 |  |  |  | 31,250 |  |  | $ | 5.00 |
| 25,000 |  |  |  | 7.50 |  |  |  | 25,000 |  |  |  | 7.50 |
| 31,250 |  |  |  | 10.00 |  |  |  | 31,250 |  |  |  | 10.00 |
| 4,167 |  |  |  | 10.86 |  |  |  |  |  |  |  |  |
| 4,167 |  |  |  | 10.86 |  |  |  |  |  |  |  |  |
| 4,167 |  |  |  | 10.86 |  |  |  |  |  |  |  |  |
| 4,167 |  |  |  | 10.86 |  |  |  |  |  |  |  |  |
| 6,250 |  |  |  | 12.50 |  |  |  | 6,250 |  |  |  | 12.50 |
| 6,250 |  |  |  | 15.00 |  |  |  | 6,250 |  |  |  | 15.00 |
| 75,000 |  |  |  | 15.18 |  |  |  | 75,000 |  |  |  | 15.18 |
| 4,000 |  |  |  | 23.41 |  |  |  |  |  |  |  |  |
| 4,000 |  |  |  | 27.60 |  |  |  |  |  |  |  |  |
| 4,000 |  |  |  | 31.74 |  |  |  |  |  |  |  |  |
| 4,000 |  |  |  | 36.50 |  |  |  |  |  |  |  |  |
| 4,000 |  |  |  | 41.98 |  |  |  |  |  |  |  |  |
| 211,668 |  |  |  |  |  |  |  | 175,000 |  |  |  |  |
The following table summarizes information about the Company’s non-vested shares as of September 30, 2017:
|  |  |  |  | Weighted |
|  |  |  |  | Average |
|  | Number of |  |  | Grant-Date |
Non-vested Shares |  | Shares |  |  | Fair Value |
Non-vested at September 30, 2016 |  |  | 6,250 |  |  | $ | 14.22 |
Granted |  |  | 36,668 |  |  | $ | 17.70 |
Vested |  |  | (6,250 | ) |  | $ | 14.22 |
Non-vested at September 30, 2017 |  |  | 36,668 |  |  | $ | 17.70 |
For stock options granted during 2017 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $8.41, and the weighted-average exercise price of such options was $10.86. For stock options granted during 2017 where the exercise price was above the stock price at the date of the grant, the weighted-average fair value of such options was $21.07, and the weighted-average exercise price for such options was $23.41. No options were granted during 2016, where the exercise price was less than the common stock price at the date of grant or where the exercise price was greater than the common stock price at the date of grant. The assumptions used in calculating the fair value of stock options granted use the Black-Scholes option pricing model for options granted in 2017 are as follows:
Risk-free interest rate |  | 1.25%
Expected life of the options |  | 5.0 to 10 years
Expected volatility |  | 107%
Expected dividend yield |  | 0%

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration